Yiqun Che

Title: Yiqun Che: Innovator in Biomedicine

Introduction

Yiqun Che is a prominent inventor based in Beijing, China. She has made significant contributions to the field of biomedicine, particularly in the area of drug resistance prediction for cancer treatment. Her innovative work has the potential to improve therapeutic outcomes for patients suffering from diffuse large B cell lymphoma.

Latest Patents

Yiqun Che holds a patent titled "Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof." This patent focuses on a biomarker that can predict drug resistance to BTK inhibitors, specifically in diffuse large B cell lymphoma cells. The biomarker identified in her research is either SMPD1 or SPHK1. This discovery is crucial for predicting the sensitivity of lymphoma cells to BTK inhibitors, thereby enhancing treatment strategies.

Career Highlights

Yiqun Che is affiliated with Beijing Friendship Hospital, Capital Medical University. Her role at this esteemed institution allows her to engage in cutting-edge research and collaborate with other experts in the field. Her dedication to advancing medical science is evident through her innovative research and patent contributions.

Collaborations

Yiqun Che has worked alongside notable colleagues, including Junhao Wei and Xinyu Han. These collaborations have fostered a dynamic research environment, leading to significant advancements in their shared field of study.

Conclusion

Yiqun Che's contributions to biomedicine, particularly through her patent on drug resistance biomarkers, highlight her role as an influential inventor. Her work not only enhances our understanding of cancer treatment but also paves the way for future innovations in the medical field.